[HTML][HTML] Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib
Y Kim, SH Lee, JS Ahn, MJ Ahn… - … and Treatment …, 2019 - synapse.koreamed.org
… efficacy data of afatinib for NSCLC harboring uncommon EGFR mutations other than
T790M. Compared with gefitinib and erlotinib, afatinib treatment … this difference did not reach …
T790M. Compared with gefitinib and erlotinib, afatinib treatment … this difference did not reach …
[HTML][HTML] Comparison of effectiveness of Gefitinib, Erlotinib, and Afatinib in advanced non-small cell lung cancer patients with EGFR mutation positive in Indonesian …
N Sutandyo, A Hanafi, M Jayusman - Chinese journal of lung …, 2019 - ncbi.nlm.nih.gov
… EGFR-tyrosine kinase inhibitors (EGFR-TKIs) were used to treat non-small cell lung cancer
(… to compare the effectiveness of first line TKIs; gefitinib, erlotinib, and afatinib in the treatment …
(… to compare the effectiveness of first line TKIs; gefitinib, erlotinib, and afatinib in the treatment …
A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
P Thomas, B Vincent, C George… - Indian Journal of …, 2019 - journals.lww.com
… erlotinib and gefitinib had similar effectiveness but gefitinib had a better safety profile
compared to erlotinib… tyrosine kinase receptor), gefitinib, erlotinib and afatinib (these target the …
compared to erlotinib… tyrosine kinase receptor), gefitinib, erlotinib and afatinib (these target the …
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
X Gu, Q Zhang, YB Chu, YY Zhao, YJ Zhang, D Kuo… - Lung Cancer, 2019 - Elsevier
… The primary objective of this study is to compare the cost-effectiveness of afatinib with
traditional chemotherapy and other EGFR-TKIs (gefitinib and erlotinib) for the first-line treatment of …
traditional chemotherapy and other EGFR-TKIs (gefitinib and erlotinib) for the first-line treatment of …
[HTML][HTML] … different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
… gefitinib or erlotinib (12). Although afatinib has superior efficacy for brain metastasis compared
… (13), its efficacy for CNS metastasis has not been fully compared with other EGFR TKIs. In …
… (13), its efficacy for CNS metastasis has not been fully compared with other EGFR TKIs. In …
[HTML][HTML] Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non …
LJ Hung, PC Hsu, CT Yang, CHS Kuo… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
… describe the effectiveness and safety of afatinib, gefitinib, and erlotinib for elderly … afatinib
required dose reductions or discontinuation compared to those treated with gefitinib or erlotinib…
required dose reductions or discontinuation compared to those treated with gefitinib or erlotinib…
Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada
… The objective of this study was to compare the cost effectiveness of first-line epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of non-small-cell …
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of non-small-cell …
Which is better EGFR-TKI followed by osimertinib: afatinib or gefitinib/erlotinib?
M Tamiya, A Tamiya, H Suzuki, K Moriizumi… - Anticancer …, 2019 - ar.iiarjournals.org
… ; p=0.017] compared with gefitinib in patients with common EGFR … given EGFR-TKI (gefitinib,
erlotinib, afatinib) proves better in … the efficacy of these drugs in patients sequentially treated …
erlotinib, afatinib) proves better in … the efficacy of these drugs in patients sequentially treated …
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
H Choi, JK Lee, HJ Oh, MS Kim, BG Kho… - Thoracic …, 2021 - Wiley Online Library
… NSCLC who progressed after prior treatment with erlotinib or gefitinib, which is similar …
afatinib because of AEs, there was no significant difference in the discontinuation rate compared …
afatinib because of AEs, there was no significant difference in the discontinuation rate compared …
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
O Arrieta, R Catalán, S Guzmán-Vazquez, F Barrón… - BMC cancer, 2020 - Springer
… the cornerstone treatment of patients with non-small cell lung … study was to compare the
cost-effectiveness of three different … cost-effectiveness analysis determined that afatinib was a …
cost-effectiveness of three different … cost-effectiveness analysis determined that afatinib was a …